...
首页> 外文期刊>Diabetes >Genetic Evidence for a Normal-Weight 'Metabolically Obese' Phenotype Linking Insulin Resistance, Hypertension, Coronary Artery Disease, and Type 2 Diabetes
【24h】

Genetic Evidence for a Normal-Weight 'Metabolically Obese' Phenotype Linking Insulin Resistance, Hypertension, Coronary Artery Disease, and Type 2 Diabetes

机译:正常体重“代谢型肥胖”表型与胰岛素抵抗,高血压,冠状动脉疾病和2型糖尿病相关的遗传证据

获取原文
获取原文并翻译 | 示例
           

摘要

The mechanisms that predispose to hypertension, coronary artery disease (CAD), and type 2 diabetes (T2D) in individuals of normal weight are poorly understood. In contrast, in monogenic primary lipodystrophy-a reduction in subcutaneous adipose tissue-it is clear that it is adipose dysfunction that causes severe insulin resistance (IR), hypertension, CAD, and T2D. We aimed to test the hypothesis that common alleles associated with IR also influence the wider clinical and biochemical profile of monogenic IR. We selected 19 common genetic variants associated with fasting insulin-based measures of IR. We used hierarchical clustering and results from genome-wide association studies of eight nondisease outcomes of monogenic IR to group these variants. We analyzed genetic risk scores against disease outcomes, including 12,171 T2D cases, 40,365 CAD cases, and 69,828 individuals with blood pressure measurements. Hierarchical clustering identified 11 variants associated with a metabolic profile consistent with a common, subtle form of lipodystrophy. A genetic risk score consisting of these 11 IR risk alleles was associated with higher triglycerides (β = 0.018; P = 4 × 10~(-29)), lower HDL cholesterol (β = -0.020; P = 7 × 10~(-37)), greater hepatic steatosis (β = 0.021; P = 3 × 10~(-4)), higher alanine trans-aminase (β = 0.002; P = 3 × 10~(-5)), lower sex-hormone-binding globulin (β = -0.010; P = 9 × 10~(-13)), and lower adiponectin (β = -0.015; P = 2 × 10~(-26)). The same risk alleles were associated with lower BMI (per-allele β = -0.008; P = 7 × 10~(-8)) and increased visceral-to-subcutaneous adipose tissue ratio (β = -0.015; P = 6 × 10~~(-7)). Individuals carrying ≥17 fasting insulin-raising alleles (5.5% population) were slimmer (0.30 kg/m~2) but at increased risk of T2D (odds ratio [OR] 1.46; per-allele P = 5 × 10~(-13)), CAD (OR 1.12; per-allele P = 1 × 10~(-5)), and increased blood pressure (systolic and diastolic blood pressure of 1.21 mmHg [per-allele P = 2 × 10~(-5)] and 0.67 mmHg [per-allele P = 2 × 10~(-4)], respectively) compared with individuals carrying ≤9 risk alleles (5.5% population). Our results provide genetic evidence for a link between the three diseases of the "metabolic syndrome" and point to reduced subcutaneous adiposity as a central mechanism.
机译:体重正常的人容易诱发高血压,冠状动脉疾病(CAD)和2型糖尿病(T2D)的机制。相反,在单基因原发性脂肪营养不良症(皮下脂肪组织的减少)中,很明显,正是脂肪功能障碍导致严重的胰岛素抵抗(IR),高血压,CAD和T2D。我们旨在检验这一假设,即与IR相关的常见等位基因也会影响更广泛的单基因IR的临床和生化特征。我们选择了与空腹胰岛素相关的IR相关的19种常见遗传变异。我们使用分级聚类和单基因IR的八个非疾病结局的全基因组关联研究结果来将这些变体分组。我们分析了针对疾病结局的遗传风险评分,包括12,171例T2D病例,40,365例CAD病例和69,828例具有血压测量结果的人。层次聚类确定了与代谢特征相关的11个变异,这些变异与常见的,微妙的脂肪营养不良形式一致。由这11个IR风险等位基因组成的遗传风险评分与较高的甘油三酸酯(β= 0.018; P = 4×10〜(-29))和较低的HDL胆固醇(β= -0.020; P = 7×10〜(- 37)),更大的肝脂肪变性(β= 0.021; P = 3×10〜(-4)),更高的丙氨酸转氨酶(β= 0.002; P = 3×10〜(-5)),较低的性激素结合球蛋白(β= -0.010; P = 9×10〜(-13))和较低的脂联素(β= -0.015; P = 2×10〜(-26))。相同风险等位基因与较低的BMI(每等位基因β= -0.008; P = 7×10〜(-8))和内脏与皮下脂肪组织比率增加有关(β= -0.015; P = 6×10 ~~(-7))。携带≥17个空腹胰岛素升高等位基因的个体(5.5%的人群)较苗条(0.30 kg / m〜2),但患T2D的风险增加(几率[OR] 1.46;每等位基因P = 5×10〜(-13 )),CAD(OR 1.12;每等位基因P = 1×10〜(-5))和血压升高(收缩压和舒张压为1.21 mmHg [每等位基因P = 2×10〜(-5) )和0.67 mmHg [每个等位基因P = 2×10〜(-4)],与携带≤9个风险等位基因的个体(5.5%人口)相比。我们的研究结果为“代谢综合征”的三种疾病之间的联系提供了遗传证据,并指出减少皮下脂肪是主要机制。

著录项

  • 来源
    《Diabetes》 |2014年第12期|4369-4377|共9页
  • 作者单位

    Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, U.K.;

    MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge, U.K.;

    Framingham Heart Study, National Heart, Lung, and Blood Institute, National Institutes of Health, Framingham, MA,Department of Biostatistics, Boston University School of Public Health, Boston, MA;

    Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, U.K.;

    Department of Internal Medicine, Division of Gastroenterology, and Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Ml;

    Clinical Pharmacology and Barts and The London Genome Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, U.K.;

    Cardiology Center, Geneva University Hospital, Geneva, Switzerland,Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD;

    Cardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, WA;

    Framingham Heart Study, National Heart, Lung, and Blood Institute, National Institutes of Health, Framingham, MA,Center for Population Studies, National Heart, Lung, and Blood Institute, National Institutes of Health, Framingham, MA,Division of Endocrinology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;

    Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, U.K.;

    Department of Genetics, Washington University School of Medicine, St. Louis, MO;

    Department of Medicine and Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA;

    University of Maryland School of Medicine, Division of Endocrinology, Baltimore, MA;

    Center for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;

    MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge, U.K.;

    Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, U.K.;

    Cardiovascular Science, National Heart and Lung Institute, Imperial College London, London, U.K.;

    Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC;

    MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge, U.K.,Department of Epidemiology and Public Health, University College London, London, U.K.;

    Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, MA,General Medicine Division, Massachusetts General Hospital, Boston, MA;

    Departments of Human Genetics and Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada;

    Department of Twin Research and Genetic Epidemiology, King's College London, London, U.K.,Department of Medicine, Human Genetics, Epidemiology, and Biostatistics, McGill University, Montreal, Quebec, Canada;

    The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, U.K.,The University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Cambridge, U.K.;

    Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, U.K.;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号